Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May 15;109(10):4119-26.
doi: 10.1182/blood-2006-12-041889. Epub 2007 Jan 18.

How I treat refractory acute GVHD

H Joachim Deeg  1
Affiliations
Review

How I treat refractory acute GVHD

H Joachim Deeg. Blood. .

Abstract

Graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) is associated with considerable morbidity and mortality, particularly in patients who do not respond to primary therapy, which usually consists of glucocorticoids (steroids). Approaches to therapy of acute GVHD refractory to "standard" doses of steroids have ranged from increasing the dose of steroids to the addition of polyclonal or monoclonal antibodies, the use of immunotoxins, additional immunosuppressive/chemotherapeutic interventions, phototherapy, and other means. While many pilot studies have yielded encouraging response rates, in most of these studies long-term survival was not improved in comparison with that seen with the use of steroids alone. A major reason for failure has been the high rate of infections, including invasive fungal, bacterial, and viral infections. It is difficult to conduct controlled prospective trials in the setting of steroid-refractory GVHD, and a custom-tailored therapy dependent upon the time after HCT, specific organ manifestations of GVHD, and severity is appropriate. All patients being treated for GVHD should also receive intensive prophylaxis against infectious complications.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Management of acute GVHD. 1Patients with grade IIa GVHD may respond to MP, 1 mg/kg, possibly combined with beclomethasone, 1-2 mg 4 times a day, and budesonide, 3 mg twice a day. In patients with grades IIb to IV GVHD, the starting dose of MP should probably be 2 mg/kg (with or without the addition of beclomethasone and budesonide). (Grade IIa is defined as skin rash of < 50% body surface area, not progressing rapidly within the first day; bilirubin < 3 mg/dL; < 20 mL nonhemorrhagic diarrhea/kg per day, without abdominal cramping. Grades IIb-IV include all cases outside the parameters defined for grade IIa.) 2The decision will likely depend upon the timing of the GVHD flare and the clinical presentation of the disease. Illustration by A. Y. Chen and H. Crawford.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 1951;12:197–201. - PubMed
    1. van Bekkum DW, de Vries MJ. Radiation Chimaeras. London, United Kingdom: Logos Press Limited; 1967. The production of radiation chimaeras. pp. 20–78.
    1. Billingham RE. The Harvey Lectures. New York, NY: Academic Press; 1966. The biology of graft-versus-host reactions; pp. 21–78. - PubMed
    1. Ferrara JLM, Cooke KR, Deeg HJ, editors. 3rd ed. New York, NY: Marcel Dekker; 2005. Graft-vs.-Host Disease.
    1. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415. - PubMed

Publication types